← 產業報告目錄

Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application [R&D, Diagnostics (Infectious Disease, Cancer)], End User (Hospital, Research Institute)-Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-05-18頁數 410報告編號 MD4473

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The market for multiplex assays is projected to be valued at approximately USD 7.15 billion in 2026 and is expected to reach USD 10.65 billion by 2031, reflecting a 8.3% growth rate. This steady growth is driven by medical institutions' growing focus on early diagnosis, accurate biomarkers, and improved patient outcomes. Factors such as the increasing complexity of diseases, the rise of personalized medicine, and the need for efficient, high-throughput testing methods are driving the growing global demand for multiplex assays. "By product & service, the consumables segment is predicted to showcase the highest CAGR during the forecast period.” The growth in this segment is primarily driven by the consistent need for multiplex assay kits, reagents, beads, primers, probes, and controls, all of which are essential for conducting analyses. The rising incidence of infectious diseases, cancers, and autoimmune conditions is expected to increase testing demand across various healthcare settings. This will boost demand for the segment in hospitals, diagnostic labs, and research facilities. Additionally, the expanding use of multiplex testing protocols and the development of new assays will further contribute to this growth. “By technology, the Flow cytometry segment is projected to hold the largest share of the multiplex assay market in 2026." This market segment is dominant due to the widespread adoption of technology in hospitals and reference laboratories, enabling high-throughput and multiparametric testing with improved sensitivity, accuracy, and reproducibility in biomarker and cell analysis. Flow cytometry is among the most widely used instruments in immunology, oncology, and translational research, owing to its ability to rapidly analyze multiple markers in a single test. The demand for flow cytometers is primarily driven by the increasing number of diagnostic tests, scientific studies, and the need for disease profiling and therapy monitoring. "The Asia Pacific is expected to register the fastest growth rate in the multiplex assay market." This region is experiencing rapid growth due to several factors, including the expansion of healthcare facilities and increased healthcare spending. The modernization of hospitals, laboratories, and diagnostic centers is also contributing to this growth. Additionally, the rising incidence of infectious diseases, cancer, and chronic conditions is driving the demand for advanced diagnostic tests. Furthermore, increased investments in biotechnology research, the expansion of pharmaceutical production facilities, and a growing number of diagnostic centers are fueling the growth of multiplex assays in the Asia Pacific region. Key countries contributing to this market growth include China, India, Japan, and South Korea, among others. The break-up of the profile of primary participants in the multiplex assay market: • By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (15%) • By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%) • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) The key players in the multiplex assay market are Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Danaher Corporation (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies (US), Quanterix Corporation (US), and bioMérieux (France). Research Coverage: This research report categorizes the multiplex assay market by product & service (consumables, instruments, software & services), type (protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays), technology (flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), other technologies), application (research & development, clinical diagnostics), end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the multiplex assay market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the multiplex assay market. This report covers the competitive analysis of upcoming startups in the multiplex assay market ecosystem. Reasons to buy this report: The report will help market leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall multiplex assay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (rising incidence of chronic and infectious diseases, advantages over singleplex and traditional assays, increasing use of multiplex assays in companion diagnostics, growing focus on early disease detection, rising incidence of chronic and infectious diseases), restraints (cost constraints associated with multiplex assay instrumentation, regulatory challenges and stringent quality standards), opportunities (growing validation of biomarkers in molecular and protein-based diagnostics, advancements in biomarker validation in molecular and protein diagnostics, expansion in emerging markets), and challenges (shortage of skilled professionals, complex data analysis and interpretation). • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assay market. • Market Development: Comprehensive information about lucrative markets; the report analyses the multiplex assay market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiplex assay market. Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), and bioMérieux (France).
目錄 Table of Contents
1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.3 STUDY SCOPE 36 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 36 1.3.2 INCLUSIONS AND EXCLUSIONS 37 1.3.3 YEARS CONSIDERED 38 1.4 CURRENCY CONSIDERED 38 1.5 STAKEHOLDERS 38 1.6 SUMMARY OF CHANGES 39 2 EXECUTIVE SUMMARY 40 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 40 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41 2.3 DISRUPTIVE TRENDS IN MULTIPLEX ASSAY MARKET 42 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 43 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44 3 PREMIUM INSIGHTS 45 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MULTIPLEX ASSAY MARKET 45 3.2 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 46 3.3 MULTIPLEX ASSAY MARKET, BY TYPE, 2026 VS. 2031 46 3.4 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031 47 3.5 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2026 VS. 2031 47 3.6 MULTIPLEX ASSAY MARKET, BY END USER, 2026 VS. 2031 48 3.7 MULTIPLEX ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48 4 MARKET OVERVIEW 49 4.1 INTRODUCTION 49 4.2 MARKET DYNAMICS 49 4.2.1 DRIVERS 50 4.2.1.1 Rising incidence of chronic and infectious diseases 50 4.2.1.2 Advantages over singleplex and traditional assays 52 4.2.1.3 Increasing use of multiplex assays in companion diagnostics 53 4.2.1.4 Growing focus on early disease detection 53 4.2.1.5 Expansion of biomarker-driven research 54 4.2.2 RESTRAINTS 55 4.2.2.1 Cost constraints associated with multiplex assay instrumentation 55 4.2.2.2 Regulatory challenges and stringent quality standards 55 4.2.3 OPPORTUNITIES 56 4.2.3.1 Growing validation of biomarkers in molecular and protein-based diagnostics 56 4.2.3.2 Expansion in emerging markets 56 4.2.4 CHALLENGES 57 4.2.4.1 Shortage of skilled professionals 57 4.2.4.2 Complex data analysis and interpretation 57 4.3 UNMET NEEDS AND WHITE SPACES 58 4.3.1 UNMET NEEDS IN MULTIPLEX ASSAY MARKET 58 4.3.2 WHITE SPACE OPPORTUNITIES 59 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 60 4.4.1 INTERCONNECTED MARKETS 60 4.4.2 CROSS-SECTOR OPPORTUNITIES 61 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 62 4.5.1 KEY MOVES AND STRATEGIC FOCUS 62 5 INDUSTRY TRENDS 63 5.1 PORTER’S FIVE FORCES ANALYSIS 63 5.1.1 BARGAINING POWER OF SUPPLIERS 64 5.1.2 BARGAINING POWER OF BUYERS 64 5.1.3 THREAT OF NEW ENTRANTS 64 5.1.4 THREAT OF SUBSTITUTES 64 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65 5.2 MACROECONOMIC INDICATORS 65 5.2.1 INTRODUCTION 65 5.2.2 GDP TRENDS AND FORECAST 65 5.3 SUPPLY CHAIN ANALYSIS 68 5.4 VALUE CHAIN ANALYSIS 69 5.5 ECOSYSTEM ANALYSIS 71 5.5.1 MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 72 5.6 PRICING ANALYSIS 72 5.6.1 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 72 5.6.2 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026 73 5.7 TRADE ANALYSIS 75 5.7.1 IMPORT SCENARIO (HS CODE 3822) 75 5.7.2 EXPORT SCENARIO (HS CODE 3822) 76 5.8 KEY CONFERENCES AND EVENTS, 2026–2027 76 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 77 5.10 INVESTMENT AND FUNDING SCENARIO 78   5.11 IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET 78 5.11.1 INTRODUCTION 78 5.11.2 KEY TARIFF RATES 79 5.11.3 PRICE IMPACT ANALYSIS 79 5.11.4 IMPACT ON REGION 80 5.11.4.1 North America 80 5.11.4.2 Europe 80 5.11.4.3 Asia Pacific 81 5.11.5 IMPACT ON END-USE INDUSTRIES 81 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 82 6.1 KEY EMERGING TECHNOLOGIES 82 6.1.1 MULTIPLEX REAL-TIME PCR 82 6.1.2 FLOW CYTOMETRY 82 6.2 COMPLEMENTARY TECHNOLOGIES 83 6.2.1 BIOINFORMATICS 83 6.2.2 MICROFLUIDICS 83 6.3 ADJACENT TECHNOLOGIES 84 6.3.1 NEXT-GENERATION SEQUENCING 84 6.3.2 DIGITAL PCR 84 6.4 TECHNOLOGY/PRODUCT ROADMAP 85 6.5 PATENT ANALYSIS 86 6.5.1 LIST OF KEY PATENTS 87 6.6 FUTURE APPLICATIONS 88 6.7 IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET 89 6.7.1 INTRODUCTION 89 6.7.2 TOP USE CASES AND MARKET POTENTIAL 90 6.7.3 KEY COMPANIES IMPLEMENTING AI 91 6.7.4 FUTURE OF AI 91 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 92 7.1 REGIONAL REGULATIONS AND COMPLIANCE 92 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 7.2 SUSTAINABILITY INITIATIVES 94 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS 94 7.2.1.1 Eco-friendly initiatives 94 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 95   8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 96 8.1 DECISION-MAKING PROCESS 96 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 96 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 96 8.2.2 BUYING CRITERIA 97 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 98 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 99 8.5 MARKET PROFITABILITY 100 8.5.1 REVENUE POTENTIAL 100 8.5.2 COST DYNAMICS 100 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 101 9 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE 102 9.1 INTRODUCTION 103 9.2 CONSUMABLES 103 9.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET 103 9.3 INSTRUMENTS 106 9.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH 106 9.4 SOFTWARE & SERVICES 109 9.4.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE 109 10 MULTIPLEX ASSAY MARKET, BY TYPE 113 10.1 INTRODUCTION 114 10.2 PROTEIN MULTIPLEX ASSAYS 114 10.2.1 BEAD-BASED PROTEIN ASSAYS 117 10.2.1.1 Best suited to study protein-protein interactions 117 10.2.2 PLANAR PROTEIN ASSAYS 120 10.2.2.1 Pivotal role in drug discovery to support uptake 120 10.2.3 OTHER PROTEIN ASSAYS 123 10.3 NUCLEIC ACID MULTIPLEX ASSAYS 125 10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS 129 10.3.1.1 Increasing infectious diseases and genetic screening tests to drive market 129 10.3.2 PLANAR NUCLEIC ACID ASSAYS 132 10.3.2.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis 132 10.3.3 OTHER NUCLEIC ACID ASSAYS 135 10.4 CELL-BASED MULTIPLEX ASSAYS 137 10.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET 137 11 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY 141 11.1 INTRODUCTION 142 11.2 FLOW CYTOMETRY 142 11.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT 142 11.3 FLUORESCENCE DETECTION 145 11.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH 145 11.4 MULTIPLEX REAL-TIME PCR 148 11.4.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS 148 11.5 LUMINESCENCE 151 11.5.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET 151 11.6 NEXT-GENERATION SEQUENCING (NGS) 154 11.6.1 RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET 154 11.7 OTHER TECHNOLOGIES 157 12 MULTIPLEX ASSAY MARKET, BY APPLICATION 161 12.1 INTRODUCTION 162 12.2 RESEARCH & DEVELOPMENT 162 12.2.1 DRUG DISCOVERY & DEVELOPMENT 165 12.2.1.1 Multiplex assays massively employed in preclinical and clinical phases 165 12.2.2 BIOMARKER DISCOVERY & VALIDATION 168 12.2.2.1 Advancing biomarker discovery through global collaborative research networks 168 12.3 CLINICAL DIAGNOSTICS 171 12.3.1 INFECTIOUS DISEASES 174 12.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays 174 12.3.2 CANCER 177 12.3.2.1 Rising burden of cancer to drive market 177 12.3.3 CARDIOVASCULAR DISEASES 181 12.3.3.1 High burden of cardiovascular diseases to support market growth 181 12.3.4 AUTOIMMUNE DISEASES 184 12.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis 184 12.3.5 NERVOUS SYSTEM DISORDERS 187 12.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment 187 12.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS 190 12.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers help in timely diagnosis 190 12.3.7 OTHER DISEASES 193 13 MULTIPLEX ASSAY MARKET, BY END USER 196 13.1 INTRODUCTION 197 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 197 13.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET 197 13.3 HOSPITALS & DIAGNOSTIC LABORATORIES 200 13.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET 200 13.4 ACADEMIC & RESEARCH INSTITUTES 203 13.4.1 RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH 203 13.5 CONTRACT RESEARCH ORGANIZATIONS 206 13.5.1 RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS 206 13.6 OTHER END USERS 209 14 MULTIPLEX ASSAY MARKET, BY REGION 213 14.1 INTRODUCTION 214 14.2 NORTH AMERICA 214 14.2.1 US 221 14.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market 221 14.2.2 CANADA 225 14.2.2.1 Favorable government initiatives to fuel market 225 14.3 EUROPE 229 14.3.1 GERMANY 234 14.3.1.1 Strong healthcare infrastructure to drive market 234 14.3.2 UK 238 14.3.2.1 Expansion of diagnostic infrastructure to drive market 238 14.3.3 FRANCE 242 14.3.3.1 Strong R&D investments and growing disease burden to drive market 242 14.3.4 ITALY 246 14.3.4.1 Growing adoption of advanced diagnostics to drive market 246 14.3.5 SPAIN 250 14.3.5.1 Rising disease burden to drive market 250 14.3.6 REST OF EUROPE 254 14.4 ASIA PACIFIC 259 14.4.1 CHINA 264 14.4.1.1 Strong healthcare investments to drive market 264 14.4.2 JAPAN 268 14.4.2.1 Universal healthcare reimbursement policy to foster market growth 268   14.4.3 INDIA 272 14.4.3.1 Increased private and public investments to bolster growth 272 14.4.4 REST OF ASIA PACIFIC 276 14.5 LATIN AMERICA 281 14.5.1 BRAZIL 286 14.5.1.1 Rising disease burden and expanding research ecosystem to drive market 286 14.5.2 MEXICO 290 14.5.2.1 Rising chronic disease burden to drive market 290 14.5.3 REST OF LATIN AMERICA 294 14.6 MIDDLE EAST & AFRICA 298 14.6.1 GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET 298 15 COMPETITIVE LANDSCAPE 303 15.1 INTRODUCTION 303 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026 303 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET 304 15.3 REVENUE ANALYSIS, 2023–2025 305 15.4 MARKET SHARE ANALYSIS, 2025 306 15.4.1 MARKET SHARE ANALYSIS, 2025 306 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 308 15.5.1 STARS 308 15.5.2 EMERGING LEADERS 308 15.5.3 PERVASIVE PLAYERS 308 15.5.4 PARTICIPANTS 308 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 310 15.5.5.1 Company footprint 310 15.5.5.2 Region footprint 310 15.5.5.3 Product & service footprint 311 15.5.5.4 Application footprint 311 15.5.5.5 End user footprint 312 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 313 15.6.1 PROGRESSIVE COMPANIES 313 15.6.2 RESPONSIVE COMPANIES 313 15.6.3 DYNAMIC COMPANIES 313 15.6.4 STARTING BLOCKS 313 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 315 15.6.5.1 Detailed list of key startups/SMEs 315 15.6.5.2 Competitive benchmarking of key startups/SMEs (1/2) 316 15.6.5.3 Competitive benchmarking of key startups/SMEs (2/2) 316   15.7 COMPANY VALUATION AND FINANCIAL METRICS 317 15.7.1 FINANCIAL METRICS 317 15.7.2 COMPANY VALUATION 317 15.8 BRAND/PRODUCT COMPARISON 318 15.9 COMPETITIVE SCENARIO 319 15.9.1 PRODUCT LAUNCHES & APPROVALS 319 15.9.2 DEALS 320 15.9.3 EXPANSIONS 321 16 COMPANY PROFILES 322 16.1 KEY PLAYERS 322 16.1.1 ILLUMINA, INC. 322 16.1.1.1 Business overview 322 16.1.1.2 Products offered 323 16.1.1.3 Recent developments 325 16.1.1.3.1 Product launches & approvals 325 16.1.1.3.2 Deals 325 16.1.1.4 MnM view 326 16.1.1.4.1 Right to win 326 16.1.1.4.2 Strategic choices 326 16.1.1.4.3 Weaknesses & competitive threats 326 16.1.2 BIO-RAD LABORATORIES, INC. 327 16.1.2.1 Business overview 327 16.1.2.2 Products offered 328 16.1.2.3 Recent developments 329 16.1.2.3.1 Product launches & approvals 329 16.1.2.3.2 Deals 330 16.1.2.4 MnM view 330 16.1.2.4.1 Right to win 330 16.1.2.4.2 Strategic choices 330 16.1.2.4.3 Weaknesses & competitive threats 330 16.1.3 THERMO FISHER SCIENTIFIC INC. 331 16.1.3.1 Business overview 331 16.1.3.2 Products offered 332 16.1.3.3 Recent developments 334 16.1.3.3.1 Product launches & approvals 334 16.1.3.3.2 Deals 334 16.1.3.4 MnM view 335 16.1.3.4.1 Right to win 335 16.1.3.4.2 Strategic choices 335 16.1.3.4.3 Weaknesses & competitive threats 335   16.1.4 DIASORIN S.P.A. 336 16.1.4.1 Business overview 336 16.1.4.2 Products offered 337 16.1.4.3 Recent developments 338 16.1.4.3.1 Product launches & approvals 338 16.1.4.3.2 Deals 339 16.1.4.4 MnM view 340 16.1.4.4.1 Right to win 340 16.1.4.4.2 Strategic choices 340 16.1.4.4.3 Weaknesses & competitive threats 340 16.1.5 BIOMÉRIEUX 341 16.1.5.1 Business overview 341 16.1.5.2 Products offered 342 16.1.5.3 Recent developments 343 16.1.5.3.1 Product launches & approvals 343 16.1.5.3.2 Deals 344 16.1.5.4 MnM view 344 16.1.5.4.1 Right to win 344 16.1.5.4.2 Strategic choices 345 16.1.5.4.3 Weaknesses & competitive threats 345 16.1.6 BECTON, DICKINSON AND COMPANY 346 16.1.6.1 Business overview 346 16.1.6.2 Products offered 347 16.1.6.3 Recent developments 348 16.1.6.3.1 Product launches & approvals 348 16.1.6.3.2 Deals 349 16.1.7 QIAGEN N.V. 350 16.1.7.1 Business overview 350 16.1.7.2 Products offered 351 16.1.7.3 Recent developments 352 16.1.7.3.1 Product launches & approvals 352 16.1.7.3.2 Deals 353 16.1.8 MERCK KGAA 354 16.1.8.1 Business overview 354 16.1.8.2 Products offered 355 16.1.8.3 Recent developments 356 16.1.8.3.1 Deals 356 16.1.8.3.2 Expansions 356   16.1.9 AGILENT TECHNOLOGIES, INC. 358 16.1.9.1 Business overview 358 16.1.9.2 Products offered 359 16.1.9.3 Recent developments 360 16.1.9.3.1 Product launches & approvals 360 16.1.9.3.2 Deals 360 16.1.10 DANAHER CORPORATION 361 16.1.10.1 Business overview 361 16.1.10.2 Products offered 362 16.1.10.3 Recent developments 363 16.1.10.3.1 Product launches & approvals 363 16.1.10.3.2 Deals 364 16.1.11 REVVITY, INC. 365 16.1.11.1 Business overview 365 16.1.11.2 Products offered 366 16.1.11.3 Recent developments 367 16.1.11.3.1 Product launches & approvals 367 16.1.11.3.2 Deals 368 16.1.12 F. HOFFMANN-LA ROCHE LTD 369 16.1.12.1 Business overview 369 16.1.12.2 Products offered 370 16.1.12.3 Recent developments 371 16.1.12.3.1 Product launches & approvals 371 16.1.12.3.2 Deals 372 16.1.13 QUANTERIX CORPORATION 373 16.1.13.1 Business overview 373 16.1.13.2 Products offered 374 16.1.13.3 Recent developments 375 16.1.13.3.1 Product launches & approvals 375 16.1.13.3.2 Deals 376 16.2 OTHER PLAYERS 377 16.2.1 BIO-TECHNE CORPORATION 377 16.2.2 SEEGENE INC. 378 16.2.3 MESO SCALE DIAGNOSTICS LLC 379 16.2.4 RANDOX LABORATORIES LTD. 380 16.2.5 STANDARD BIOTOOLS INC. 381 16.2.6 HOLOGIC, INC. 382 16.2.7 ABBOTT LABORATORIES 383 16.2.8 SIEMENS HEALTHINEERS AG 384 16.2.9 ENZO BIOCHEM INC. 385 16.2.10 SHIMADZU CORPORATION 386 16.2.11 PROMEGA CORPORATION 387 16.2.12 BOSTER BIOLOGICAL TECHNOLOGY 388 17 RESEARCH METHODOLOGY 389 17.1 RESEARCH DATA 389 17.1.1 SECONDARY RESEARCH 390 17.1.1.1 Key data from secondary sources 391 17.1.2 PRIMARY DATA 392 17.1.2.1 Primary sources 392 17.1.2.2 Key data from primary sources 393 17.1.2.3 Key industry insights 394 17.2 MARKET SIZE ESTIMATION 395 17.2.1 BOTTOM-UP APPROACH 396 17.2.1.1 Approach 1: Company revenue estimation approach 396 17.2.1.2 Approach 2: Presentations of companies and primary interviews 397 17.2.1.3 Growth forecast 397 17.2.2 TOP-DOWN APPROACH 398 17.3 MARKET BREAKDOWN AND DATA TRIANGULATION 399 17.4 MARKET SHARE ANALYSIS 399 17.5 RESEARCH ASSUMPTIONS 400 17.5.1 PARAMETRIC ASSUMPTIONS 400 17.5.2 GROWTH RATE ASSUMPTIONS 400 17.6 RESEARCH LIMITATIONS 401 17.7 RISK ASSESSMENT 401 18 APPENDIX 402 18.1 DISCUSSION GUIDE 402 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 406 18.3 CUSTOMIZATION OPTIONS 408 18.4 RELATED REPORTS 408 18.5 AUTHOR DETAILS 409
圖表清單 List of Tables & Figures
TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV (ALL AGES): 2010, 2023, AND 2024 (MILLION PEOPLE) 51 TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES IN BOTH SEXES: AGE 0-85+, 2022–2045 51 TABLE 3 TOTAL TB INCIDENCE, 2024 51 TABLE 4 IMPACT OF PORTER’S FIVE FORCES ON MULTIPLEX ASSAY MARKET 64 TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 65 TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS 66 TABLE 7 EUROPE: MACROECONOMIC INDICATORS 67 TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS 67 TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS 67 TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 67 TABLE 11 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 73 TABLE 12 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026 (USD) 74 TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 75 TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 76 TABLE 15 MULTIPLEX ASSAY MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 76 TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 79 TABLE 17 KEY PATENTS IN MULTIPLEX ASSAY MARKET, 2022–2026 87 TABLE 18 KEY COMPANIES IMPLEMENTING AI IN MULTIPLEX ASSAY MARKET 91 TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 97 TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 97 TABLE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES 98 TABLE 27 MULTIPLEX ASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 99 TABLE 28 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 103 TABLE 29 MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 104 TABLE 30 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 104 TABLE 31 EUROPE: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 105 TABLE 32 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 105 TABLE 33 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 106 TABLE 34 GLOBAL: NUMBER OF MULTIPLEX ANALYZERS INSTALLED, 2024–2031 (UNITS) 107 TABLE 35 MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 36 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 37 EUROPE: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 38 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 39 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 40 MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 41 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 42 EUROPE: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 43 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 44 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 45 MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 114 TABLE 46 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 115 TABLE 47 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 48 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 49 EUROPE: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 50 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 51 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 52 MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 53 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 54 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 55 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 56 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 57 MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 58 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 59 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 60 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 61 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 62 MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 63 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 64 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 65 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 66 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 67 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA 126 TABLE 68 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 127 TABLE 69 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 70 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 71 EUROPE: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 72 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 73 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 74 MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 75 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 76 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 77 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 78 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 79 MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 80 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 81 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 82 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 83 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 84 MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 85 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 86 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 87 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 88 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 89 MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 90 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 91 EUROPE: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 92 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 93 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 94 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 142 TABLE 95 MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 96 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 97 EUROPE: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 98 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 99 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 100 MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 101 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 102 EUROPE: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 103 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 104 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 105 MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 106 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 107 EUROPE: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 109 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 110 MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 111 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 112 EUROPE: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 113 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 114 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 115 MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2024–2031 (USD MILLION) 155 TABLE 116 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 117 EUROPE: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 118 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 119 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 120 MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 121 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 122 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 123 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 124 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 125 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 162 TABLE 126 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 127 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 128 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 129 EUROPE: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 130 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 131 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 132 MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 133 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 134 EUROPE: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 135 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 136 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 137 MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 138 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 139 EUROPE: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 140 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 141 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 142 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 143 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 144 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 145 EUROPE: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 146 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 147 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 148 MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 149 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 150 EUROPE: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 151 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 152 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 153 ESTIMATED NUMBER OF CANCER CASES IN BOTH SEXES (AGE 0-85+), BY REGION, 2022 VS. 2030 178 TABLE 154 MULTIPLEX ASSAY MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 155 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 156 EUROPE: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 157 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 158 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 159 MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 160 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 161 EUROPE: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 162 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 163 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 164 MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 165 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 166 EUROPE: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 167 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 168 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 169 MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 170 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 171 EUROPE: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 172 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 173 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 174 MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 175 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 176 EUROPE: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 177 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 178 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 179 MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION) 193 TABLE 180 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 181 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 182 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 183 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 184 MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 197 TABLE 185 MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 186 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 187 EUROPE: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 188 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 189 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 190 MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 201 TABLE 191 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 192 EUROPE: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 193 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 194 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 195 MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 204 TABLE 196 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 197 EUROPE: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 198 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 199 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 200 MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 207 TABLE 201 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 202 EUROPE: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 203 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 204 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 205 MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 210 TABLE 206 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 207 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 208 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 209 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 210 MULTIPLEX ASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 214 TABLE 211 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 215 TABLE 212 NORTH AMERICA: MACROECONOMIC INDICATORS 217 TABLE 213 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 214 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 217 TABLE 215 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 216 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 217 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 218 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 219 TABLE 219 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 219 TABLE 220 NORTH AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 221 NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 222 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 223 US: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 221 TABLE 224 US: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 225 US: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 226 US: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 227 US: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 223 TABLE 228 US: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 223 TABLE 229 US: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 230 US: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 231 US: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 224 TABLE 232 CANADA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 225 TABLE 233 CANADA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 234 CANADA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 235 CANADA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 236 CANADA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 227 TABLE 237 CANADA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 227 TABLE 238 CANADA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 239 CANADA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 240 CANADA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 228 TABLE 241 EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 230 TABLE 242 MACROECONOMIC INDICATORS FOR EUROPE 230 TABLE 243 EUROPE: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 244 EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 231 TABLE 245 EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 246 EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 247 EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 248 EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 232 TABLE 249 EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 233 TABLE 250 EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 251 EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 252 EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 253 GERMANY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 235 TABLE 254 GERMANY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 255 GERMANY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 256 GERMANY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 257 GERMANY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 236 TABLE 258 GERMANY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236 TABLE 259 GERMANY: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 260 GERMANY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 261 GERMANY: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 238 TABLE 262 UK: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 239 TABLE 263 UK: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 264 UK: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 265 UK: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 266 UK: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240 TABLE 267 UK: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 240 TABLE 268 UK: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 269 UK: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 270 UK: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 271 FRANCE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 243 TABLE 272 FRANCE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 273 FRANCE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 274 FRANCE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 275 FRANCE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 244 TABLE 276 FRANCE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 245 TABLE 277 FRANCE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 278 FRANCE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 279 FRANCE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 280 ITALY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 247 TABLE 281 ITALY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 282 ITALY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 283 ITALY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 284 ITALY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 248 TABLE 285 ITALY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249 TABLE 286 ITALY: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 287 ITALY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 288 ITALY: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 289 SPAIN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 251 TABLE 290 SPAIN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 291 SPAIN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 292 SPAIN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 293 SPAIN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 252 TABLE 294 SPAIN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252 TABLE 295 SPAIN: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 296 SPAIN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 297 SPAIN: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 298 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 255 TABLE 299 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 300 REST OF EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 301 REST OF EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 302 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257 TABLE 303 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257 TABLE 304 REST OF EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 305 REST OF EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 306 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 258 TABLE 307 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 260 TABLE 308 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 309 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 261 TABLE 310 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 311 ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 312 ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 313 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262 TABLE 314 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263 TABLE 315 ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 316 ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 317 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 318 CHINA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 265 TABLE 319 CHINA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 320 CHINA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 321 CHINA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 322 CHINA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266 TABLE 323 CHINA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 324 CHINA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 325 CHINA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 326 CHINA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268 TABLE 327 JAPAN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 269 TABLE 328 JAPAN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 329 JAPAN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 330 JAPAN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 331 JAPAN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 270 TABLE 332 JAPAN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271 TABLE 333 JAPAN: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 334 JAPAN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 335 JAPAN: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 336 INDIA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 273 TABLE 337 INDIA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 338 INDIA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 339 INDIA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 340 INDIA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 274 TABLE 341 INDIA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 275 TABLE 342 INDIA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 343 INDIA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 344 INDIA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 276 TABLE 345 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 277 TABLE 346 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 347 REST OF ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 348 REST OF ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 349 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 279 TABLE 350 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 279 TABLE 351 REST OF ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 352 REST OF ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 353 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 354 MACROECONOMIC INDICATORS FOR LATIN AMERICA 281 TABLE 355 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 356 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 282 TABLE 357 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 358 LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 359 LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 360 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 284 TABLE 361 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 284 TABLE 362 LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 363 LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 364 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 285 TABLE 365 BRAZIL: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 287 TABLE 366 BRAZIL: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 367 BRAZIL: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 368 BRAZIL: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 369 BRAZIL: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 288 TABLE 370 BRAZIL: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 288 TABLE 371 BRAZIL: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 372 BRAZIL: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 373 BRAZIL: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 290 TABLE 374 MEXICO: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 291 TABLE 375 MEXICO: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 376 MEXICO: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 377 MEXICO: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 378 MEXICO: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 292 TABLE 379 MEXICO: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 293 TABLE 380 MEXICO: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 381 MEXICO: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 382 MEXICO: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 294 TABLE 383 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 295 TABLE 384 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 385 REST OF LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 386 REST OF LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 387 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 296 TABLE 388 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 297 TABLE 389 REST OF LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 390 REST OF LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 391 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 298 TABLE 392 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 299 TABLE 393 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 394 MIDDLE EAST & AFRICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 395 MIDDLE EAST & AFRICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 396 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 301 TABLE 397 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 301 TABLE 398 MIDDLE EAST & AFRICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 399 MIDDLE EAST & AFRICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 400 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 302 TABLE 401 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MULTIPLEX ASSAY MARKET, JANUARY 2023−APRIL 2026 304 TABLE 402 MULTIPLEX ASSAY MARKET: DEGREE OF COMPETITION 306 TABLE 403 MULTIPLEX ASSAY MARKET: REGION FOOTPRINT 310 TABLE 404 MULTIPLEX ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT 311 TABLE 405 MULTIPLEX ASSAY MARKET: APPLICATION FOOTPRINT 311 TABLE 406 MULTIPLEX ASSAY MARKET: END USER FOOTPRINT 312 TABLE 407 MULTIPLEX ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 315 TABLE 408 MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (1/2) 316 TABLE 409 MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (2/2) 316 TABLE 410 MULTIPLEX ASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 319 TABLE 411 MULTIPLEX ASSAY MARKET: DEALS, JANUARY 2023–APRIL 2026 320 TABLE 412 MERCK KGAA: EXPANSIONS, JANUARY 2023– APRIL 2026 321 TABLE 413 ILLUMINA, INC.: COMPANY OVERVIEW 322 TABLE 414 ILLUMINA, INC: PRODUCTS OFFERED 323 TABLE 415 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 325 TABLE 416 ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026 325 TABLE 417 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 327 TABLE 418 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 328 TABLE 419 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 329 TABLE 420 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026 330 TABLE 421 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 331 TABLE 422 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 332 TABLE 423 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 334 TABLE 424 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 334 TABLE 425 DIASORIN S.P.A.: COMPANY OVERVIEW 336 TABLE 426 DIASORIN S.P.A.: PRODUCTS OFFERED 337 TABLE 427 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 338 TABLE 428 DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026 339 TABLE 429 BIOMÉRIEUX: COMPANY OVERVIEW 341 TABLE 430 BIOMÉRIEUX: PRODUCTS OFFERED 342 TABLE 431 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 343 TABLE 432 BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026 344 TABLE 433 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 346 TABLE 434 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 347 TABLE 435 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 348 TABLE 436 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023–APRIL 2026 349 TABLE 437 QIAGEN N.V.: COMPANY OVERVIEW 350 TABLE 438 QIAGEN N.V.: PRODUCTS OFFERED 351 TABLE 439 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 352 TABLE 440 QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026 353 TABLE 441 MERCK KGAA: COMPANY OVERVIEW 354 TABLE 442 MERCK KGAA: PRODUCTS OFFERED 355 TABLE 443 MERCK KGAA: DEALS, JANUARY 2023–APRIL 2026 356 TABLE 444 MERCK KGAA: DEALS, JANUARY 2023– APRIL 2026 356 TABLE 445 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 358 TABLE 446 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 359 TABLE 447 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 360 TABLE 448 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–APRIL 2026 360 TABLE 449 DANAHER CORPORATION: COMPANY OVERVIEW 361 TABLE 450 DANAHER CORPORATION: PRODUCTS OFFERED 362 TABLE 451 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 363 TABLE 452 DANAHER CORPORATION: DEALS, JANUARY 2023–APRIL 2026 364 TABLE 453 REVVITY, INC.: COMPANY OVERVIEW 365 TABLE 454 REVVITY, INC.: PRODUCTS OFFERED 366 TABLE 455 REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 367 TABLE 456 REVVITY, INC.: DEALS, JANUARY 2023–APRIL 2026 368 TABLE 457 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 369 TABLE 458 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 370 TABLE 459 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 371 TABLE 460 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–APRIL 2026 372 TABLE 461 QUANTERIX CORPORATION: COMPANY OVERVIEW 373 TABLE 462 QUANTERIX CORPORATION: PRODUCTS OFFERED 374 TABLE 463 QUANTERIX CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 375 TABLE 464 QUANTERIX CORPORATION: DEALS, JANUARY 2023–APRIL 2026 376 TABLE 465 BIO-TECHNE CORPORATION: COMPANY OVERVIEW 377 TABLE 466 SEEGENE INC.: COMPANY OVERVIEW 378 TABLE 467 MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW 379 TABLE 468 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 380 TABLE 469 STANDARD BIOTOOLS INC.: COMPANY OVERVIEW 381 TABLE 470 HOLOGIC, INC.: COMPANY OVERVIEW 382 TABLE 471 ABBOTT LABORATORIES: COMPANY OVERVIEW 383 TABLE 472 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 384 TABLE 473 ENZO BIOCHEM INC.: COMPANY OVERVIEW 385 TABLE 474 SHIMADZU CORPORATION: COMPANY OVERVIEW 386 TABLE 475 PROMEGA CORPORATION: COMPANY OVERVIEW 387 TABLE 476 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 388 TABLE 477 MULTIPLEX ASSAY MARKET: RISK ASSESSMENT 401 FIGURE 1 MULTIPLEX ASSAY MARKET SEGMENTATION 36 FIGURE 2 MARKET HIGHLIGHTS AND KEY INSIGHTS 40 FIGURE 3 MULTIPLEX ASSAY MARKET, 2024–2031 41 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025 41 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MULTIPLEX ASSAY MARKET 42 FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN MULTIPLEX ASSAY MARKET, 2026-2031 43 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 44 FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 45 FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 46 FIGURE 10 PROTEIN MULTIPLEX ASSAYS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 46 FIGURE 11 MULTIPLEX REAL-TIME PCR SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 47 FIGURE 12 RESEARCH & DEVELOPMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 47 FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 48 FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 48 FIGURE 15 MULTIPLEX ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49 FIGURE 16 MULTIPLEX ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 63 FIGURE 17 MULTIPLEX ASSAY MARKET: SUPPLY CHAIN ANALYSIS 69 FIGURE 18 MULTIPLEX ASSAY MARKET: VALUE CHAIN ANALYSIS 70 FIGURE 19 MULTIPLEX ASSAY MARKET: ECOSYSTEM ANALYSIS 71 FIGURE 20 MULTIPLEX ASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 77 FIGURE 21 NUMBER OF DEALS AND FUNDING ACTIVITIES IN MULTIPLEX ASSAY MARKET 78 FIGURE 22 APPLIED AND GRANTED PATENTS, 2016–2025 86 FIGURE 23 MARKET POTENTIAL OF AI IN MULTIPLEX ASSAY MARKET 90 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 96 FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 97 FIGURE 26 NORTH AMERICA: MULTIPLEX ASSAY MARKET SNAPSHOT 216 FIGURE 27 ASIA PACIFIC: MULTIPLEX ASSAY MARKET SNAPSHOT 260 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025 (USD MILLION) 305 FIGURE 29 MULTIPLEX ASSAY MARKET SHARE ANALYSIS, 2025 306 FIGURE 30 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 309 FIGURE 31 MULTIPLEX ASSAY MARKET: COMPANY FOOTPRINT 310 FIGURE 32 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 314 FIGURE 33 EV/EBITDA OF KEY VENDORS 317 FIGURE 34 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 317 FIGURE 35 MULTIPLEX ASSAY MARKET: BRAND/PRODUCT COMPARISON FOR MULTIPLEX INSTRUMENTS 318 FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 323 FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 328 FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 332 FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 337 FIGURE 40 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 342 FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 347 FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 351 FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 355 FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 359 FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 362 FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2025) 366 FIGURE 47 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 370 FIGURE 48 QUANTERIX CORPORATION: COMPANY SNAPSHOT (2025) 374 FIGURE 49 RESEARCH DESIGN 389 FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 395 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 395 FIGURE 52 MULTIPLEX ASSAY MARKET: REVENUE SHARE ANALYSIS 396 FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 397 FIGURE 54 TOP-DOWN APPROACH 398 FIGURE 55 DATA TRIANGULATION METHODOLOGY 399

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們